Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Miquel Roca, Annalisa Bonelli, Agnese Cattaneo, Alessandro Comandini, Giorgio Di Dato, Franca Heiman, Valeria Pegoraro, Siegfried Kasper, Hans-Peter Volz & Diego Palao. (2023) Factors associated with sick leave duration in patients suffering from major depressive disorder initiating antidepressant treatment: a real-world evidence study in Germany and Spain. International Journal of Psychiatry in Clinical Practice 27:1, pages 59-68.
Read now
Read now
Siegfried Kasper, Annalisa Bonelli, Agnese Cattaneo, Alessandro Comandini, Giorgio Di Dato, Franca Heiman, Valeria Pegoraro, Diego Palao, Miquel Roca & Hans-Peter Volz. (2021) Predictors of sick leave days in patients affected by major depressive disorder receiving antidepressant treatment in general practice setting in Germany. International Journal of Psychiatry in Clinical Practice 25:4, pages 393-402.
Read now
Read now
Eric Q. Wu, Paul E. Greenberg, Elaine Yang, Andrew P. Yu, Rym Ben-Hamadi & M. Haim Erder. (2009) Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: a comparison between escitalopram and other SSRI/SNRIs. Journal of Medical Economics 12:2, pages 124-135.
Read now
Read now
Feng Xie, Nicolas Despiegel, Natalya Danchenko & Karina Hansen. (2009) Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder. International Journal of Psychiatry in Clinical Practice 13:1, pages 59-69.
Read now
Read now
Cyril Höschl & Jaromír Švestka. (2008) Escitalopram for the treatment of major depression and anxiety disorders. Expert Review of Neurotherapeutics 8:4, pages 537-552.
Read now
Read now
Edward P. Armstrong, Daniel C. Malone & M. Haim Erder. (2008) A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder. Current Medical Research and Opinion 24:4, pages 1115-1121.
Read now
Read now
Raymond W Lam & Lieven Annemans. (2007) Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders. Expert Review of Pharmacoeconomics & Outcomes Research 7:6, pages 559-576.
Read now
Read now
Christophe Lançon, Patrice Verpillat, Lieven Annemans, Nicolas Despiegel & Clément François. (2007) Escitalopram in major depressive disorder: clinical benefits and cost effectiveness versus citalopram. International Journal of Psychiatry in Clinical Practice 11:1, pages 44-52.
Read now
Read now
Jan Sørensen, Kurt B. Stage, Niels Damsbo, Agathe Le Lay & Michiel E. Hemels. (2007) A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care. Nordic Journal of Psychiatry 61:2, pages 100-108.
Read now
Read now
Alan G. Wade, Idris Toumi & Michiel E. H. Hemels. (2005) A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. Current Medical Research and Opinion 21:4, pages 631-641.
Read now
Read now
Articles from other publishers (16)
Mark P. Connolly, Cole Tashjian, Nikolaos Kotsopoulos, Aomesh Bhatt & Maarten J. Postma. (2016) A comparison of average wages with age-specific wages for assessing indirect productivity losses: analytic simplicity versus analytic precision. The European Journal of Health Economics 18:6, pages 697-701.
Crossref
Crossref
Colleen E. Carney, Jack D. Edinger, Maragatha Kuchibhatla, Angela M. Lachowski, Olya Bogouslavsky, Andrew D. Krystal & Colin M. Shapiro. (2017) Cognitive Behavioral Insomnia Therapy for Those With Insomnia and Depression: A Randomized Controlled Clinical Trial. Sleep 40:4.
Crossref
Crossref
Lieven Annemans, Mélanie Brignone, Sylvain Druais, Ann De Pauw, Aline Gauthier & Koen Demyttenaere. (2014) Cost-Effectiveness Analysis of Pharmaceutical Treatment Options in the First-Line Management of Major Depressive Disorder in Belgium. PharmacoEconomics 32:5, pages 479-493.
Crossref
Crossref
Mark J.C. Nuijten, Mélanie Brignone, Florence Marteau, Johan A. den Boer & Erik Hoencamp. (2012) Cost-Effectiveness of Escitalopram in Major Depressive Disorder in the Dutch Health Care Setting. Clinical Therapeutics 34:6, pages 1364-1378.
Crossref
Crossref
Göran Nordström, Natalya Danchenko, Nicolas Despiegel & Florence Marteau. (2012) Cost-Effectiveness Evaluation in Sweden of Escitalopram Compared with Venlafaxine Extended-Release as First-Line Treatment in Major Depressive Disorder. Value in Health 15:2, pages 231-239.
Crossref
Crossref
Marieke Krol, Jocé Papenburg, Marc Koopmanschap & Werner Brouwer. (2012) Do Productivity Costs Matter?. PharmacoEconomics 29:7, pages 601-619.
Crossref
Crossref
Regina Rendas-Baum, Min Yang, Joseph Gricar & Gene V. Wallenstein. (2010) Cost-Effectiveness Analysis of Treatments for Premenstrual Dysphoric Disorder. Applied Health Economics and Health Policy 8:2, pages 129-140.
Crossref
Crossref
Dietmar Winkler, Edda Pjrek, Ulrike Moser & Siegfried Kasper. (2007) Escitalopram in a working population: results from an observational study of 2378 outpatients in Austria. Human Psychopharmacology: Clinical and Experimental 22:4, pages 245-251.
Crossref
Crossref
P. M. Llorca & J.-L. Fernandez. (2007) Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation. International Journal of Clinical Practice 61:4, pages 702-710.
Crossref
Crossref
Bruno Fantino, Nicholas Moore, H??l??ne Verdoux & Jean-Paul Auray. (2007) Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder. International Clinical Psychopharmacology 22:2, pages 107-115.
Crossref
Crossref
Hamid Sadri & Nicole Mittmann. (2016) A Qualitative Review of Recent Economic Evaluations of Escitalopram. Journal of Pharmacy Technology 23:1, pages 35-40.
Crossref
Crossref
María Velasco, Luis Salvador, Carmelo Juárez & Fernando Antoñanzas. (2013) Análisis de coste-efectividad de escitalopram comparado con citalopram en el tratamiento de pacientes con depresión mayor grave. PharmacoEconomics Spanish Research Articles 3:2, pages 63-73.
Crossref
Crossref
Dietmar Winkler, Edda Pjrek & Siegfried Kasper. (2006) Gender-specific symptoms of depression and anger attacks. The Journal of Men's Health & Gender 3:1, pages 19-24.
Crossref
Crossref
David Murdoch & Susan J Keam. (2005) Escitalopram. Drugs 65:16, pages 2379-2404.
Crossref
Crossref
Koen Demyttenaere, Michiel E.H. Hemels, Joumana Hudry & Lieven Annemans. (2005) A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium. Clinical Therapeutics 27:1, pages 111-124.
Crossref
Crossref
. (2005) Current awareness in human psychopharmacology. Human Psychopharmacology: Clinical and Experimental 20:1, pages 75-86.
Crossref
Crossref